Erratum to: Clofarabine in the treatment of poor risk acute myeloid leukaemia (Hematological Oncology, (2010), (118–123), 10.1002/hon.922);Clofarabine in the treatment of poor risk acute myeloid leukaemia

Hematological Oncology

Volumn 28, Issue 3, 2010, Pages 118-123

  Krawczyk, Janusz ^a   Ansar, Naeem ^a   Swords, Ronan ^a   Murphy, Tracy ^a   MacDonagh, Barry ^a   Meenaghan, Teresa ^a   Hayden, Patrick ^a   Hayad, Amjad ^a   Murray, Margaret ^a   O'Dwyer, Michael ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Acute myeloid leukaemia; Clofarabine; J26 elderly; Poor risk; Refractory; Relapsed

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TYPHLITIS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77957315407     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2911     Document Type: Erratum

References (14)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995; 45(1): 8-30.
2. Osman H, Murray M, Egan E, O'Dwyer M. Outcome of elderly acute myeloid leukaemia. Ir Med J 2008; 101(10).
3. Menzin J, Boulanger L, Karsten V, Cahill AL, Earle CE. Effects of initial treatment on survival among elderly AML patients: findings from the SEER-medicare database. ASH Annual Meeting Abstracts 2006; 108(11): 1973.
4. Burnett AK, Baccarani M, Johnson P, et al. Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy. ASH Annual Meeting Abstracts 2006; 108(11): 1985.
5. Erba HP, Kantarjian H, Claxton DF, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. ASH Annual Meeting Abstracts 2008; 112(11): 558.
6. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105(3): 940-947.
7. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112(5): 1638-1645.
8. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102(7): 2379-2386.
9. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA. Synthesis and biological activity of 2′-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenine. J Med Chem 1992; 35(2): 397-401.
10. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21(6): 1167-1173. (Pubitemid 46594149)
11. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103(2): 479-485.
12. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108(1): 63-73.
13. Burnett AK, Baccarani M, Johnson P, Yin J, Russell N. Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy. J Clin Oncol (Meeting Abstracts) 2006 June 20. 2006; 24 (18-suppl): 6513.
14. Zhang Y, Zhang J, Shahriar M, Lim SH. Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. ASH Annual Meeting Abstracts 2008; 112(11): 379.